|  |  |  |
| --- | --- | --- |
|  | **Males** | **Females** |
|  | **nT** | **nnT** | **p value** | **nT** | **nnT** | **p value** |
| **n** (%) | 265 (29.4) | 636 (70.6) | - | 75 (39.3) | 116 (60.7) | - |
| **Age** (years) | 71.2 ±4.7 | 71.2 ±4.8 | 0.780 | 71.8 ±5.0 | 71.3 ±4.7 | 0.650 |
| **Ethnicity**, n (%)**Caucasian****African****South-American****Other** |  264(99.6)1 (0.4)0 (0)0 (0) | 626 (98.4)6 (0.9)3 (0.5)1 (0.2) | 0.761 | 74 (98.7)1 (1.3)0 (0)0 (0) | 112 (96.6)2 (1.7)2 (1.7)0 (0) | 0.589 |
| **Body mass index** (Kg/m2) | 26.1 ±3.9 | 25.7 ±4.1 | 0.211 | 25.9 ±5.7 | 24.3 ±4.5 | 0.073 |
| **Chronic HCV infection**, n (%) | 34 (14.3) | 78 (13.6) | 0.480 | 6 (9.8) | 12 (12.1) | 0.693 |
| **Chronic HBV infection**, n (%) | 18 (7.8) | 67 (12.7) | 0.07 | 6 (10.5) | 9 (9.3) | 0.416 |
| **Active smokers**, n (%) | 56 (25.6) | 144 (27.1) | 0.855 | 11 (20) | 18 (20.7) | 0.963 |
| **CD4+ cell count** (cells/uL) | 819 ±260 | 540 ±250 | <0.001 | 813 ±234 | 530 ±244 | <0.001 |
| **normalized CD4+ cell percentage** | 235 (88.7) | 179 (28.1) | <0.001 | 65 (86.7) | 38 (32.8) | <0.001 |
| **CD8+ cell count** (cells/uL) | 579 ±209 | 941 ±470 | <0.001 | 577 ±216 | 890 ±453 | <0.001 |
| **normalized CD8+ cell percentage** | 256 (96.6) | 290 (45.6) | <0.001 | 71 (94.7) | 69 (59.5) | <0.001 |
| **CD4+/CD8+ ratio** | 1.70 ±2.66 | 0.65 ±0.30 | <0.001 | 1.50 ±0.46 | 0.70 ±0.40 | <0.001 |
| **Nadir CD4+ cell count** (cell/uL) | 310 ±229 | 184 ±148 | <0.001 | 238 ±168 | 195 ±142 | 0.065 |
| **HIV duration** (years) | 16 ±7.1 | 16.4 ±7.3 | 0.333 | 15.5 ±6 | 15.8 ±7.1 | 0.944 |
| **HIV duration**, n (%)**<10 years****10-20 years****>20 years** | 64 (24.2)124 (47)76 (28.8) | 152 (24.3)294 (47)180 (28.8) | 0.989 | 18 (24.7)40 (54.8)15 (20.5) | 27 (23.7)53 (46.5)34 (29.8) | 0.351 |
| **Plasma HIV RNA <50 cps/mL**, n (%)**Log10 copies/mL above 50** | 248 (98.4)2.23 ±0.42 | 578 (94)2.51 ±0.98 | 0.0050.581 | 69 (97.2)2 ±0.25 | 105 (92.9)2.10 ±0.30 | 0.2140.692 |
| **HANA conditions**, n (%)**Chronic kidney disease****Bone disease****Cardiovascular disease****Lipid abnormalities****Type2 Diabetes****Hypertension****Cancer****Cirrhosis****COPD** | 39 (20.1)34 (24.5)46 (25.8)141 (74.2)52 (28.3)132 (70.2)26 (15.3)10 (5.3)7 (4) | 97 (20.4)99 (25.6)93 (21)318 (68.5)139 (31)291 (62.3)108 (25.2)26 (5.5)41 (9.5) | 0.9260.7940.1950.1500.5020.0560.0090.9180.022 | 10 (15.4)24 (42.9)4 (7.1)48 (77.4)18 (30)40 (65.6)9 (16.1)2 (3.5)1 (1.8) | 18 (22.5)37 (47.4)4 (5.3)52 (65)16 (20.5)45 (57.7)19 (25.3)4 (5.3)2 (2.7) | 0.2800.6000.6550.1080.2000.3440.2010.6300.722 |
| **Multimorbidity**, n (%) | 77 (55.8) | 173 (47.5) | 0.098 | 28 (54.9) | 29 (42) | 0.163 |
| **Polypharmacy**, n (%) | 52 (38.2) | 139 (41.7) | 0.483 | 11 (25.6) | 18 (32.1) | 0.477 |

**Supplementary Table 1. Baseline demographic and therapeutic characteristics stratified by gender.** “nT”, normalized T cell subsets (CD4+/CD8+ratio>1 and CD4+ >500 cells/uL); “nnT”, non normalized T cell subsets; “SD”, standard deviation; normalized CD4+ cell percentage (between 32 and 61%); normalized CD8 cell percentage (between 14 and 43%); “HANA”, HIV-associated non AIDS conditions, “COPD”, chronic obstructive pulmonary disease. P-values are obtained using parametric tests (t-test and Fisher’s exact test) comparing nT and nnT patients within each gender.